A significant body of new research underscores the critical importance of a nuanced approach to assessing renal health, revealing that a notable divergence between two established blood markers can serve as a potent predictor for severe health outcomes, including the progression to kidney failure, cardiovascular disease, and premature mortality. This groundbreaking analysis highlights how inconsistencies between creatinine and cystatin C measurements, two widely accepted indicators of kidney function, frequently signal an underlying vulnerability that might otherwise remain undetected through conventional screening methods.
For decades, medical professionals have predominantly relied on serum creatinine levels to estimate glomerular filtration rate (eGFR), a key measure of how efficiently the kidneys filter waste products from the blood. Creatinine, a metabolic byproduct of muscle activity, has been a cornerstone in nephrology due to its ease of measurement and established correlation with kidney function. However, its utility is not without limitations. Creatinine levels can be influenced by various non-renal factors such as muscle mass, dietary protein intake, age, sex, and even certain medications, leading to potential inaccuracies in assessing true kidney health, particularly in individuals with atypical body compositions or specific clinical conditions. For instance, a very muscular individual might have a higher creatinine level despite healthy kidneys, while an elderly or frail person with reduced muscle mass could present with seemingly normal creatinine despite significant renal impairment.
More recently, medical guidelines have increasingly advocated for the concurrent measurement of cystatin C, a small protein produced at a constant rate by virtually all nucleated cells in the body. Unlike creatinine, cystatin C levels are less susceptible to variations in muscle mass, diet, and age, offering a potentially more precise and stable indicator of renal filtration capacity. Its ubiquitous production and filtration primarily through the glomeruli make it a valuable complement to creatinine. The rationale behind utilizing both markers concurrently is to harness their respective strengths and compensate for their individual weaknesses, thereby furnishing a more comprehensive and accurate profile of a patient’s kidney status and prospective health trajectory.
An extensive international investigation spearheaded by researchers at NYU Langone Health has brought to light a concerning prevalence of substantial discrepancies between creatinine and cystatin C results, particularly within the cohort of hospitalized patients. This large-scale analysis revealed that over one-third of individuals admitted to hospitals exhibited cystatin C readings that suggested a renal function at least 30% poorer than what their creatinine levels indicated. This significant gap, according to the study authors, represents a critical diagnostic blind spot, potentially masking underlying renal dysfunction or systemic illness that would otherwise evade detection by either test in isolation.
Dr. Morgan Grams, a co-corresponding author of the study and the Susan and Morris Mark Professor of Medicine at NYU Grossman School of Medicine, emphasized the profound implications of these findings. "Our research decisively underscores the imperative of simultaneously measuring both creatinine and cystatin C to achieve a truly comprehensive understanding of kidney performance, especially in older adults and those with complex medical histories," Dr. Grams stated. She elaborated that by evaluating both biomarkers, clinicians can identify a significantly larger proportion of individuals grappling with compromised kidney function, and crucially, at an earlier stage in the disease progression, effectively mitigating the diagnostic shortcomings inherent in relying solely on one marker. The research was published in the esteemed Journal of the American Medical Association and simultaneously presented at the American Society of Nephrology’s annual Kidney Week conference, highlighting its significance within the nephrology community.
The accurate quantification of kidney function extends far beyond mere disease diagnosis; it is an indispensable parameter for guiding safe and effective medication dosing. The kidneys play a pivotal role in metabolizing and excreting a vast array of pharmaceuticals, including life-saving cancer treatments, potent antibiotics, and numerous commonly prescribed drugs. An impaired renal system can lead to drug accumulation, resulting in toxicity, while an overestimation of kidney function can lead to underdosing, rendering treatments ineffective. Therefore, precise kidney function measurements are paramount in preventing adverse drug reactions and optimizing therapeutic outcomes, a point reiterated by Dr. Grams, who also holds a professorship in the Department of Population Health at NYU Grossman School of Medicine.
This study builds upon a broader understanding of chronic kidney disease (CKD) as a burgeoning global health crisis. In a separate, concurrently released study, the same research group reported a stark increase in the worldwide prevalence of CKD, now ranking as the ninth leading cause of death globally. Dr. Grams underscored that enhanced tools for early detection, such as the combined biomarker approach, could empower patients to initiate appropriate interventions sooner, potentially averting the need for drastic measures like lifelong dialysis or kidney transplantation. Early identification offers a critical window for implementing lifestyle modifications, managing comorbidities like hypertension and diabetes, and administering nephroprotective medications, all of which can slow disease progression and preserve remaining kidney function.
The current investigation represents an unprecedented undertaking in its scope and scale, meticulously analyzing medical records, blood test results, and demographic data from an astonishing 860,966 adults across six distinct nationalities. All participants underwent simultaneous measurements of both creatinine and cystatin C on the same day and were subsequently monitored for an average period of eleven years. The rigorous analytical framework carefully accounted for numerous confounding factors known to influence these biomarkers independently of kidney function, including smoking status, obesity, and a history of cancer, thereby strengthening the validity of the observed associations.
Conducted under the auspices of the international Chronic Kidney Disease Prognosis Consortium, this research stands as the largest inquiry to date exploring the intricate relationship between discrepancies in these two renal markers and long-term health outcomes. The consortium, a collaborative global initiative, was established with the overarching mission to deepen the understanding of CKD, standardize its definitions, and refine risk stratification models worldwide. Its extensive network and data pooling capabilities were instrumental in facilitating a study of this magnitude and impact.
The study’s findings were unequivocal: individuals whose cystatin C results indicated a glomerular filtration rate at least 30% lower than their creatinine results faced significantly elevated risks across a spectrum of adverse health events. These included a heightened probability of all-cause mortality, the development of cardiovascular disease, and the onset of heart failure. Furthermore, this group demonstrated a greater propensity to progress to severe chronic kidney disease, ultimately necessitating renal replacement therapies such as dialysis or organ transplantation. Notably, similar patterns of increased risk were observed in a substantial proportion (11%) of outpatients and individuals who, at the time of initial testing, appeared to be in good health, highlighting the insidious nature of this "hidden" kidney dysfunction.
Despite the compelling evidence for cystatin C’s utility, its adoption into routine clinical practice has been slow. Dr. Grams highlighted that the international organization Kidney Disease — Improving Global Outcomes (KDIGO) first issued recommendations for cystatin C testing as early as 2012. Yet, a 2019 survey revealed that fewer than 10% of clinical laboratories in the United States were performing the test in-house. While this situation has improved with major laboratory companies like Quest Diagnostics and Labcorp now offering the assay, its widespread utilization remains suboptimal.
Dr. Josef Coresh, also a co-corresponding author of the study and the director of NYU Langone’s Optimal Aging Institute, underscored the urgency for physicians to embrace this advanced diagnostic tool. "These results emphatically emphasize the necessity for clinicians to leverage the increasing availability of cystatin C testing in hospitals and healthcare facilities," Dr. Coresh urged. He cautioned that without incorporating this second marker, medical practitioners risk overlooking invaluable diagnostic insights into their patients’ overall well-being and potential future medical challenges. Dr. Coresh, who is also the Terry and Mel Karmazin Professor of Population Health at NYU Grossman School of Medicine, cited alarming data from the study, noting that among hospitalized Americans included in the analysis, fewer than 1% had actually undergone cystatin C testing, underscoring a significant gap between scientific evidence and clinical implementation.
This pivotal research received financial backing from National Institutes of Health grant R01DK100446 and the National Kidney Foundation, reflecting its recognized importance in advancing renal health. The collaborative spirit of the study was evident in its diverse authorship. Dr. Michelle Estrella from the University of California, San Francisco, served as the study’s first author, while Dr. Kai-Uwe Eckardt of Charite-Universitatsmedizin Berlin in Germany was the senior author. Alongside Drs. Grams and Coresh, who are key leaders of the Chronic Kidney Disease Prognosis Consortium, significant contributions from NYU Langone included Dr. Shoshana Ballew, Ms. Yingying Sang, and Dr. Aditya Surapaneni. The global reach of the research effort was further strengthened by the participation of additional investigators from esteemed institutions across the United States, Europe, Asia, and Australia, bringing together a wealth of expertise to address this critical public health issue.
About the Author
